SCHEMBL553790

SCHEMBL553790

COc1ccccc1Oc1ccc(N)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.79
MAPK1 P28482 3/20 0.79
L3MBTL1 Q9Y468 2/20 0.79
HTT P42858 2/20 0.79
NCOA1 Q15788 1/20 0.56
NCOA3 Q9Y6Q9 1/20 0.56
MAOA P21397 1/20 0.56
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA4 P22748 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
CA14 Q9ULX7 1/20 0.54
TDP1 Q9NUW8 5/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
CYP3A4 P08684 2/20 0.52
TSHR P16473 2/20 0.52
MAPT P10636 3/20 0.50
ADRA2B P18089 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29553492 1.00 ALDH1A1 (0.79) ALDH1A1MAPK1L3MBTL1HTTNCOA1
SCHEMBL459355 0.89 MAOA (0.68) ALDH1A1MAPK1L3MBTL1HTTNCOA1
SCHEMBL3627857 0.89 HTT (1.00) ALDH1A1MAPK1L3MBTL1HTTCA12
SCHEMBL1270920 0.89 MAOA (0.68) ALDH1A1MAPK1L3MBTL1HTTNCOA1
SCHEMBL29476109 0.89 MAOA (0.68) ALDH1A1MAPK1L3MBTL1HTTNCOA1
SCHEMBL487016 0.87 MAOA (0.73) ALDH1A1MAPK1L3MBTL1HTTNCOA1
SCHEMBL1270898 0.87 MAOA (0.65) ALDH1A1MAPK1L3MBTL1HTTNCOA1
SCHEMBL6290292 0.87 MAOA (0.65) ALDH1A1MAPK1L3MBTL1HTTNCOA1
SCHEMBL2252749 0.87 MAOA (0.65) ALDH1A1MAPK1L3MBTL1HTTNCOA1
SCHEMBL486843 0.87 MAOA (0.73) ALDH1A1MAPK1L3MBTL1HTTNCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051335-A1 TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2025-02-13 US disclosed
EP-4368182-A1 TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS Consejo Superior De Investigaciones Científicas - CSIC (ES) 2024-05-15 EP disclosed
WO-2023281149-A1 TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2023-01-12 WO disclosed
US-11289238-B2 Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) 2022-03-29 US disclosed
US-11286359-B2 Prepreg and carbon fiber-reinforced composite material TORAY INDUSTRIES, INC. (JP) 2022-03-29 US disclosed
EP-3760633-B1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2021-12-15 EP disclosed
US-11111345-B2 Prepreg and carbon fiber-reinforced composite material TORAY INDUSTRIES, INC. (JP) 2021-09-07 US disclosed
US-20210174983-A1 COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC 2021-06-10 US disclosed
WO-2021112933-A1 COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) 2021-06-10 WO disclosed
EP-3800285-A1 SIZING-AGENT-COATED CARBON FIBRE BUNDLE, CARBON-FIBRE-BUNDLE PRODUCTION METHOD, AND PREPREG Toray Industries, Inc. (JP) 2021-04-07 EP disclosed
EP-1178965-B1 QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES ASTRAZENECA AB (SE) 2003-09-24 EP disclosed
EP-1337524-A1 SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS AstraZeneca AB (SE) 2003-08-27 EP disclosed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed
WO-2002044166-A1 SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2002-06-06 WO disclosed
EP-1178965-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES AstraZeneca AB (SE) 2002-02-13 EP disclosed
EP-1178966-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES AstraZeneca AB (SE) 2002-02-13 EP disclosed
EP-1178967-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES AstraZeneca AB (SE) 2002-02-13 EP disclosed
WO-2000068201-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES ASTRAZENECA AB (SE) 2000-11-16 WO disclosed
WO-2000068200-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES ASTRAZENECA AB (SE) 2000-11-16 WO disclosed
WO-2000068199-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES ASTRAZENECA AB (SE) 2000-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051335-A1 TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS TTBK1, TTBK2, MAPT ALDH1A1 3733/4885MAPK1 427/4885L3MBTL1 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.